As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”

In response to the coronavirus pandemic, Christian Angermayer—the world's largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.

The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.

After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.

Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?

Shlomi Raz, CEO of Eleusis Benefit Corporation, made false claims about psychedelics. We asked multiple ethnobotanists, a medical anthropologist, and a chemist if they could help us set the record straight.

Could a liquid-delivery system meant to help maintain a personalized “scent bubble” quietly usher in the creation of wearable psychedelic microdosing technology? A U.S. patent for this system is just one among an increasing list of psychedelic-inspired intellectual properties.

With the recent creation of the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine in Baltimore, Maryland, we must remember that, while industrialized medicine has never attempted to serve all people, institutional histories vary from one organization to the next.

The Multidisciplinary Association for Psychedelic Studies (MAPS) submitted their MDMA PTSD expanded access protocol to the FDA on January 14, 2019.

Until MDMA-assisted psychotherapy is proven without a doubt to reduce long-term costs, many insurance companies do not have an incentive to cover it.

What does MDMA rescheduling mean for the recreational user? If you are under the impression that MDMA is on its way to being rescheduled, across the board, you may be disappointed.

What does the future hold for MDMA? We explore MAPS' ongoing FDA phase 3 clinical trials, rescheduling, health insurance, and expanded access. 

Comedian Shane Mauss and Zendo Project's Ryan Beauregard on psychedelic-induced psychosis. “It was really easy once I got past the big video game, ‘Truman Show’ feeling, to get to a place of, ‘oh, that was all in my head. I was crazy.’"

If there are other harm-reduction organizations, such as DanceSafe, that are able to distribute test kits, then we won’t attend that event....the ones that refuse DanceSafe, we come in and do it anyways.

The research team at UConn studying MDMA-assisted psychotherapy for PTSD is now defunct.

psychedelic.support could soon become a useful asset to anyone interested in the professional world of psychedelic-related therapy.

As venture-capital-backed, for-profit companies barrel into psychedelic therapy, the potential for the widespread privatization of psychedelic knowledge and profits looms large. Some researchers are so enthusiastic about medicalization by “any means necessary” that they’re resorting to prohibitionist historical narratives and calling for monopolies to push the agenda forward.

We talked with Johns Hopkins psychedelic researcher, Alan Kooi Davis, about the Source Research Foundation, a non-profit awarding grants to students researching psychedelics.

We spoke with an experienced psychiatrist about how exactly prescribing ketamine for depression works.

A team of researchers bathed octopuses in MDMA. Here's what they learned.